EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSMZEG00005009269
Gene Symbol: MAP3K13
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSMZEG00005004868
Gene Symbol: MAP3K5
3 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSMZEG00005016425
Gene Symbol: MAP3K8
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSMZEG00005010764
Gene Symbol: MAP3K9
3 Cross references
193 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSMZEG00005008293
Gene Symbol: LOC101470425
3 Cross references
208 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSMZEG00005024017
Gene Symbol: MLNR
3 Cross references
174 Possible Orthologues:

Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1

Ensembl ID : ENSMZEG00005013636
Gene Symbol: LOC101473126
2 Cross references
195 Possible Orthologues:

Mucosal Pentraxin

Ensembl ID : ENSMZEG00005015166
Gene Symbol: LOC101465998
2 Cross references
408 Possible Orthologues:

Mucosal Pentraxin-Like

Ensembl ID : ENSMZEG00005015161
Gene Symbol: LOC101466289
2 Cross references
347 Possible Orthologues:

Muscarinic Acetylcholine Receptor M2

Ensembl ID : ENSMZEG00005019144
Gene Symbol: LOC101469188
2 Cross references
185 Possible Orthologues:

Muscarinic Acetylcholine Receptor M4

Ensembl ID : ENSMZEG00005019014
Gene Symbol: LOC101471221
2 Cross references
184 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSMZEG00005021256
Gene Symbol: NPR3
3 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).